Rising CEA Levels After Breast Cancer Treatment: Is It Metastasis? - Oncology

More Info

---

The situation you describe regarding your mother's rising CEA (Carcinoembryonic Antigen) levels after her breast cancer treatment raises important questions about the potential for metastasis. It is essential to understand that while elevated CEA levels can be an indicator of cancer recurrence or metastasis, they are not definitive on their own.
CEA is a tumor marker that is often used in monitoring certain types of cancers, including breast cancer. In general, normal CEA levels are considered to be below 5 ng/mL, although this can vary slightly depending on the laboratory. Your mother's CEA levels have shown a gradual increase from 3.8 ng/mL at the end of her chemotherapy to 6.2 ng/mL in July. While this increase is concerning, it is crucial to interpret these results in the context of her overall clinical picture.

The fact that your mother underwent a thorough examination, including endoscopies of the stomach and colon, which returned normal results, is a positive sign. It suggests that there may not be any immediate evidence of metastasis in those areas. However, the rising CEA levels, combined with her history of breast cancer, warrant further investigation. The decision by her physician to refer her for a PET-CT scan is appropriate, as this imaging modality can provide more detailed information about the presence of cancerous lesions in the body.

It is important to note that CEA levels can be influenced by various factors, including smoking, inflammation, and other benign conditions. Therefore, while an increase in CEA levels can be indicative of cancer activity, it is not a definitive marker for metastasis. The PET-CT scan will help clarify whether there are any new or recurrent cancerous lesions that could explain the rising CEA levels.

In summary, while the rising CEA levels are concerning and could suggest the possibility of metastasis, they are not conclusive on their own. The upcoming PET-CT scan will be critical in determining whether there is any evidence of cancer spread. It is essential to maintain open communication with your mother's healthcare team, as they can provide the most accurate interpretation of her test results and guide her treatment options based on the findings.
In the context of breast cancer, especially after treatment, regular monitoring and follow-up are vital. If metastasis is confirmed, treatment options may include additional chemotherapy, targeted therapy, or other modalities depending on the specific characteristics of the cancer. It is also important for family members to be aware of the potential hereditary risks associated with breast cancer, as genetic factors can play a role in the likelihood of developing similar conditions in relatives.

In conclusion, while rising CEA levels can be a cause for concern, they are not definitive proof of metastasis. The upcoming PET-CT scan will provide more clarity, and it is essential to work closely with healthcare providers to navigate the next steps in your mother's care.